Listen
Reason for request
Inclusion on the list of medicines reimbursed by National Insurance (boxes of 30 and 90) and approved for use by hospitals (boxes of 30, 50 and 90).
-
Clinical Benefit
| Substantial |
The actual benefit of AXELER products is substantial. |
Clinical Added Value
| no clinical added value |
AXELER 20 mg/5 mg, 40 mg/5 mg and 40 mg/10 mg fixed-dose combinations of olmesartan medoxomil 20 or 40 mg and amlodipine besilate 5 or 10 mg provide no improvement in actual benefit (IAB V) in comparison with concurrent use of the two active substances taken separately. |
English version
Contact Us
Évaluation des médicaments
